News

Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths
YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...
Dermatology Advisor11h
Metabolic Syndrome Increases Pain Catastrophizing in Psoriatic Arthritis
Metabolic syndrome is associated with elevated levels of pain catastrophizing among patients with PsA and may impact disease activity.
European Medical Journal9h
Osteoarthritis Surgery Reviewed: Risks, Results, and Recommendations
A new review examines the effectiveness of surgical treatments for severe osteoarthritis, highlighting the dominance of total ...
Rheumatology Advisor12h
Adverse Outcomes Still Common in Responsive and Monophasic Lupus Nephritis
Roughly 26% of patients with LN demonstrated a responsive and monophasic disease course, which was linked to older age and shorter SLE duration at LN onset.